Durham’s Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment
Durham-based Biomarck Pharmaceuticals has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer.
Read More
